Patents by Inventor Weijia Ou
Weijia Ou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11833215Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: June 4, 2020Date of Patent: December 5, 2023Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
-
Publication number: 20230270876Abstract: The present invention provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination.Type: ApplicationFiled: March 6, 2023Publication date: August 31, 2023Inventors: Bernhard Hubert Geierstanger, Weijia Ou, Tetsuo Uno
-
Patent number: 11596695Abstract: The present invention provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination.Type: GrantFiled: December 3, 2019Date of Patent: March 7, 2023Assignee: Novartis AGInventors: Bernhard Hubert Geierstanger, Weijia Ou, Tetsuo Uno
-
Publication number: 20210170043Abstract: Provided herein are immunoconjugates comprising an anti-DC-SIGN antibody conjugated to a STING agonist. Also disclosed are methods of making the immunoconjugates and methods of treating cancer using the immunoconjugates.Type: ApplicationFiled: October 30, 2019Publication date: June 10, 2021Inventors: Lisa BARNETT, Steven BENDER, Charles Y. CHO, Sarah COX, Jonathan Deane, Scott Martin GLASER, Xueshi Hao, Shailaja KASIBHATLA, Weijia OU, Tetsuo UNO, Yongqin WAN, Ben WEN, Tom Yao-Hsiang WU
-
Publication number: 20200405875Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: June 4, 2020Publication date: December 31, 2020Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William Mallet, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
-
Publication number: 20200338207Abstract: The present invention provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination.Type: ApplicationFiled: December 3, 2019Publication date: October 29, 2020Applicant: NOVARTIS AGInventors: Bernhard Hubert Geierstanger, Weijia Ou, Tetsuo Uno
-
Patent number: 10787480Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: GrantFiled: June 12, 2019Date of Patent: September 29, 2020Assignee: Novartis AGInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang
-
Patent number: 10786578Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: July 27, 2015Date of Patent: September 29, 2020Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
-
Publication number: 20190382441Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: ApplicationFiled: June 12, 2019Publication date: December 19, 2019Inventors: Bernhard Hubert GEIERSTANGER, Jan GRUNEWALD, Yunho JIN, Weijia OU, Tetsuo UNO, Yongqin WAN, Xing WANG
-
Patent number: 10392421Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: GrantFiled: April 24, 2018Date of Patent: August 27, 2019Assignee: Novartis AGInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang
-
Publication number: 20190194315Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: ApplicationFiled: June 17, 2016Publication date: June 27, 2019Applicant: Novartis AGInventors: Tinya ABRAMS, Steven Bruce COHEN, Joseph Anthony D'Alessio, Jason Damiano, Clemens Durr, Bernhard Hubert GEIERSTANGER, Qi-Ying HU, Thomas HUBER, Hidetomo IMASE, Yunho JIN, Daniel MENEZES, Kathy MILLER, Morvarid MOHSENI, Weijia OU, Katherine RENDAHL, Tetsuo UNO, Yongqin WAN, Xing WANG
-
Patent number: 10280139Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: GrantFiled: November 27, 2017Date of Patent: May 7, 2019Assignee: Novartis AGInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia Ou, Shifeng Pan, Tetsuo Uno, Yongqin Wan, Xing Wang
-
Publication number: 20180244717Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: ApplicationFiled: April 24, 2018Publication date: August 30, 2018Inventors: Bernhard Hubert GEIERSTANGER, Jan GRUNEWALD, Yunho JIN, Weijia OU, Tetsuo UNO, Yongqin WAN, Xing WANG
-
Publication number: 20180193475Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: July 27, 2015Publication date: July 12, 2018Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William MALLET, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
-
Publication number: 20180155281Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: ApplicationFiled: November 27, 2017Publication date: June 7, 2018Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia OU, Shifeng Pan, Tetsuo Uno, Yongqin Wan, Xing Wang
-
Patent number: 9988420Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: GrantFiled: December 17, 2014Date of Patent: June 5, 2018Assignee: Novartis AGInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang, Yunho Jin
-
Patent number: 9938323Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.Type: GrantFiled: November 5, 2015Date of Patent: April 10, 2018Assignee: Novartis AGInventors: Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno
-
Patent number: 9884817Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: GrantFiled: June 11, 2015Date of Patent: February 6, 2018Assignee: Novartis AGInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia Ou, Shifeng Pan, Tetsuo Uno, Yongqin Wan, Xing Wang
-
Publication number: 20170355731Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.Type: ApplicationFiled: November 5, 2015Publication date: December 14, 2017Inventors: Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno
-
Publication number: 20170121282Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: ApplicationFiled: June 11, 2015Publication date: May 4, 2017Applicant: NOVARTIS AGInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia OU, Shifeng Pan, Tetsuo Uno, Yongqin Wan, Xing Wang